Abstract
Although genistein has been shown to inhibit tumorigenesis in a variety of human cancers including pancreatic cancer (PC), the exact molecular mechanism of its anti-cancer effects has not yet been fully elucidated. Recently, microRNAs (miRNAs) have been reported to regulate multiple aspects of tumor development and progression, indicating that targeting miRNAs could be a novel strategy to treat human cancers. In the current study, we investigated whether a natural compound genistein could down-regulate onco-miR-223, resulting in the inhibition of cell growth and invasion, and induction of apoptosis in PC cells. We found that genistein treatment significantly inhibited miR-223 expression and up-regulated Fbw7, one of the targets of miR-223. Moreover, down-regulation of miR-223 inhibited cell growth and induced apoptosis in PC cells. These findings suggest that genistein exerts its anti-tumor activity partly through downregulation of miR-223 in PC cells.
Keywords: miR-223, Fbw7, apoptosis, cell growth, genistein, pancreatic cancer.
Current Drug Targets
Title:Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells
Volume: 14 Issue: 10
Author(s): Jia Ma, Long Cheng, Hao Liu, Jing Zhang, Ying Shi, Fanpeng Zeng, Lucio Miele, Fazlul H Sarkar, Jun Xia and Zhiwei Wang
Affiliation:
Keywords: miR-223, Fbw7, apoptosis, cell growth, genistein, pancreatic cancer.
Abstract: Although genistein has been shown to inhibit tumorigenesis in a variety of human cancers including pancreatic cancer (PC), the exact molecular mechanism of its anti-cancer effects has not yet been fully elucidated. Recently, microRNAs (miRNAs) have been reported to regulate multiple aspects of tumor development and progression, indicating that targeting miRNAs could be a novel strategy to treat human cancers. In the current study, we investigated whether a natural compound genistein could down-regulate onco-miR-223, resulting in the inhibition of cell growth and invasion, and induction of apoptosis in PC cells. We found that genistein treatment significantly inhibited miR-223 expression and up-regulated Fbw7, one of the targets of miR-223. Moreover, down-regulation of miR-223 inhibited cell growth and induced apoptosis in PC cells. These findings suggest that genistein exerts its anti-tumor activity partly through downregulation of miR-223 in PC cells.
Export Options
About this article
Cite this article as:
Ma Jia, Cheng Long, Liu Hao, Zhang Jing, Shi Ying, Zeng Fanpeng, Miele Lucio, Sarkar H Fazlul, Xia Jun and Wang Zhiwei, Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990187
DOI https://dx.doi.org/10.2174/13894501113149990187 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
Emerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Progress in Drug Delivery, Therapeutic Strategies, and Nursing Practices: Enhancing Diagnostics and Clinical Outcomes in Complex Diseases
The recent advancements in drug delivery systems as well as therapeutics have significantly improved therapy effectiveness combined with better patient results specifically for difficult disease management. The modern pharmaceutical research field makes drug targeting its main priority because this approach strengthens therapeutic agents' precision while improving their effectiveness. Multiple delivery ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Assessment of Adverse Drug Reaction Due to Cancer Chemotherapy in a Teaching Oncology Hospital in Isfahan, Central of Iran
Reviews on Recent Clinical Trials A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Protein Informatics and Vaccine Development: Cancer Case Study
Current Topics in Medicinal Chemistry Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Artificial Chaperone Polysaccharide Nanogels for Protein Delivery: A Thermodynamic Study of Protein-Nanogel Interactions Using Fluorescence Correlation Spectroscopy
Current Drug Discovery Technologies DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design A Comprehensive Review on Pharmacological Properties of Abrus precatorius L.
The Natural Products Journal Unraveling Potential Candidate Targets Associated with Expression of p16<sup>INK4a</sup> or p16 Truncated Fragment by Comparative Proteomics Analysis
Current Proteomics Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Structure and Functional Relationships of Hsp90
Current Cancer Drug Targets Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Current Drug Targets Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug
Anti-Cancer Agents in Medicinal Chemistry Research Progress of Exogenous Plant MiRNAs in Cross-Kingdom Regulation
Current Bioinformatics